Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Roche Holding (SWX:ROP) has delivered a 25.0% total return over the past year, contrasting with negative moves over the past 3 months and year to date. This gives investors a mixed picture of its recent performance.
See our latest analysis for Roche Holding.
The recent 10% three-month share price decline to CHF313.1 contrasts with a 25.0% one-year total shareholder return. This suggests that shorter term momentum is fading after a stronger period for long term holders.
If you are weighing Roche Holding against other healthcare names, it could be a useful moment to broaden your watchlist with 125 healthcare AI stocks
With shares at CHF313.1 and an indicated discount to both analyst targets and some intrinsic estimates, the key question is whether Roche is quietly undervalued or whether the market is already pricing in its future growth potential.
Roche Holding’s most followed valuation narrative points to a fair value of CHF352 per share, compared to the last close at CHF313.1, putting a spotlight on what is driving that gap.
Next generation sequencing, the cobas Mass Spec 601 platform, broader neurology and infectious disease assays, and a growing companion diagnostics portfolio position Roche to benefit from rising use of complex diagnostics in clinical decision making, with potential to lift Diagnostics sales growth and core operating profit over time.
Curious what earnings mix, margin profile and long range revenue path sit behind that fair value, and how they tie into this diagnostics push? The narrative connects specific growth assumptions, profitability targets and a lower future P/E, all discounted back at a defined rate. The details matter, especially how much of the CHF352 rests on Diagnostics doing more of the heavy lifting.
Result: Fair Value of CHF352 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this depends on China pricing pressure easing and key late stage drugs clearing clinical and regulatory hurdles, both of which could challenge the current story.
Find out about the key risks to this Roche Holding narrative.
The mix of positives and concerns around Roche can feel finely balanced, so act while the details are fresh and check the full picture for yourself with 5 key rewards and 1 important warning sign
Roche may or may not stay on your list, but you do not want to miss other opportunities that match your goals just as well.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROP.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com